Aldeyra Therap

Q2 FY2026 EarningsQ2 FY26 net loss was narrower than consensus, with GAAP EPS of -$0.09 vs. -$0.08 expected, and a GAAP net loss of $5.45M compared to the anticipated $4.54M loss. Operating loss of $5.85M was higher than the estimated $4.46M due to increased stock-based compensation and G&A expenses. The quarter was defined by the full repayment of the $15M Hercules Capital debt, leaving the company debt-free with a cash runway extending into 2H 2028. Reproxalap remains in a regulatory stalemate following the March 2026 CRL, with a critical Type D meeting with the FDA scheduled for late Q3 2026.